TORONTO, Nov. 1, 2011 /CNW/ - Apotex Inc., the largest Canadian owned
pharmaceutical company, launched today Apo-Esomeprazole, a generic
version of AstraZeneca's Nexium®, a gastric proton pump inhibitor
(PPI). With initial launches to the provinces of Québec, Nova Scotia,
New Brunswick, and Ontario, Apotex has now released product to the
remainder of the Canadian market. The brand product costs the public
and private healthcare budgets close to $300 million per year.
Apotex is the only generic pharmaceutical company to have successfully
litigated the Nexium® patents, bringing the first generic alternative
to market 8 years prior to all patents expiring.
With this latest victory, Apotex has led the legal charge to genericize
4 out of 5 major products in the class of gastric PPI molecules -
including Omeprazole, Pantoprazole, Lansoprazole and now
Esomeprazole. These legal efforts are estimated to deliver a cumulative
savings of $6.5 billion to Canada's healthcare system. Also, the above
mentioned products are Canadian made from the development, research, to
"Generic litigant frontrunners such as Apotex play a critical role in
maintaining affordability of our healthcare system. Apo-Esomeprazole is
yet another example of our commitment to provide patients with
affordable, high-quality medicines, despite the potential risks and
consequences we often face in bringing these new generic products to
market," stated Mr. Jack Kay, Apotex President.
Due to Canada's dual patent litigation system, companies such as Apotex
are often faced with years of ongoing litigation with brand companies
in order to continue selling generic products. Such the case with
Apo-Esomeprazole, as the brand has initiated a patent infringement
action against Apotex over Nexium®.
"The support of Public and Private stakeholders is critical to help fuel
our ongoing pursuit to deliver more savings to Canada's healthcare
system," concluded Mr. Kay.
Apotex has over 6,000 employees in 21 facilities, producing 300
pharmaceuticals that are exported to 115 countries. It is the top
pharmaceutical R&D company in Canada with planned expenditures of $2
billion over the next ten years. Apotex is also the only significant
Canadian producer of active pharmaceutical chemicals.
Trademarks are owned by their respective owners.
SOURCE Apotex Inc.
For further information:
Director, Public & Government Affairs
Tel: 416-749-9300, ext. 7366
Fax: (416) 401-3835